“…Recently, miR-197 has been identified as an oncomiR in hepatocellular carcinoma [20], non-small-cell lung cancer [21], pancreatic cancer [22] and male breast cancer [23]. However, other studies revealed that miR-197 was down-regulated in esophageal cancer [24], oral carcinoma [25], gastric carcinoma [26], osteosarcoma [27] and astrocytomas [28], and might exert an anti-cancer effect on these cancers. This discrepancy may be attributed to the distinct miRNA signatures of organ/tissue-specificity and temporal expression patterns.…”